SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
about
Epigenetic modulators as therapeutic targets in prostate cancerIdentification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data AnalysisThe long noncoding RNA SPRIGHTLY acts as an intranuclear organizing hub for pre-mRNA moleculesExploiting Epigenetic Alterations in Prostate Cancer.SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression.Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorHsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC)New open conformation of SMYD3 implicates conformational selection and allostery.Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway.SET and MYND domain containing protein 3 in cancer.Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.MiR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma.ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.Epigenetic Regulation in Prostate Cancer Progression.Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
P2860
Q28071912-7798F869-3174-42C7-9D84-F3C76009D500Q31068011-40D3BAC3-0878-4E37-84FA-928EA854B53EQ33633347-E626B858-AE29-4C67-9A55-D79FC5B09821Q33755160-8D2D8F79-A2DC-4075-9200-F02ADEA2901DQ33812604-D5132D04-983A-428D-85C8-5F7E07FE12BCQ33838513-442C51D9-F42A-498E-9DE6-75AE8033106EQ35960316-69BD5EC8-36BE-4776-90F0-4EFF1247C670Q36946799-D0D848E1-E42A-4525-9391-D50B9E2E7324Q37392616-612459B6-547E-4BD7-8362-F109A63E0F51Q37520511-8B8A9CF2-4C23-488F-8316-C2502F555A9DQ37536404-680648FD-5F9B-44EB-A2F5-6318F04E7BD2Q37588369-269C763F-B73D-459D-B22C-9A498EE979F4Q37596853-92D56D36-9A12-49CB-98B3-8DF1EFA270E1Q38430339-A98F9CC3-A5B8-4798-916A-B51CDB3A07EBQ38740526-6B9E2724-E4E5-4DAE-B22D-1C481A8B7ABEQ38811194-53FB9558-4AF4-4318-B723-771E761C7C51Q39055609-1AA7982E-B076-4FB2-9431-3187951C4479Q42317470-A075F9F3-BE23-4254-9EFD-0863FC0E4202Q42371520-0ABCE0A8-4E64-4912-8354-B971F5DE33F2Q47116779-ACE756B9-F5A9-484D-86AB-193772B64B67Q54974720-EAEAB009-A023-4A4C-A337-09381076F48BQ57816641-6F12DEED-0BF7-4E9B-9F4B-A7C96057BFC5
P2860
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
SMYD3 contributes to a more ag ...... ts Cyclin D2 through H4K20me3.
@en
type
label
SMYD3 contributes to a more ag ...... ts Cyclin D2 through H4K20me3.
@en
prefLabel
SMYD3 contributes to a more ag ...... ts Cyclin D2 through H4K20me3.
@en
P2093
P2860
P356
P1433
P1476
SMYD3 contributes to a more ag ...... ts Cyclin D2 through H4K20me3.
@en
P2093
Carmen Jerónimo
Diogo Almeida-Rios
Elsa Joana Sousa
Filipa Quintela Vieira
Inês Graça
Isa Carneiro
Maria Inês Godinho
Pedro Costa-Pinheiro
Rui Henrique
Sara Monteiro-Reis
P2860
P304
13644-13657
P356
10.18632/ONCOTARGET.3767
P407
P577
2015-05-01T00:00:00Z